Insulin analogues in children with Type 1 diabetes: A 52-week randomized clinical trial

Diabetic Medicine

Volumn 30, Issue 2, 2013, Pages 216-225

  Thalange, N ^a   Bereket, A ^b   Larsen, J ^c   Hiort, L C ^c   Peterkova, V ^d  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c NOVO NORDISK A S   (Denmark)

^d ENDOCRINOLOGY RESEARCH CENTRE   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN ISOPHANE INSULIN; INSULIN ASPART; INSULIN DETEMIR; ISOPHANE INSULIN; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BODY WEIGHT; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOCTURNAL HYPOGLYCEMIA; OPEN STUDY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN ASPART; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MALE; TREATMENT OUTCOME;

EID: 84872742136     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12041     Document Type: Article

References (35)

1. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341: 1306-1309.
2. The Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289-1298.
3. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-309.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
5. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
6. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed) 1985; 290: 811-815.
7. Amin R, Widmer B, Prevost AT, Schwarze P, Cooper J, Edge J et al. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. Br Med J 2008; 336: 697-701.
8. Perantie DC, Lim A, Wu J, Weaver P, Warren SL, Sadler M et al. Effects of prior hypoglycemia and hyperglycemia on cognition in children with type 1 diabetes mellitus. Pedriatr Diabetes 2008; 9: 87-95.
9. Gonder-Frederick LA, Zrebiec JF, Bauchowitz AU, Ritterband LM, Magee JC, Cox DJ et al. Cognitive function is disrupted by both hypo- and hyperglycemia in school-aged children with type 1 diabetes: a field study. Diabetes Care 2009; 32: 1001-1006.
10. Silverstein J, Klingensmith G, Copeland K, Plotnick L, Kaufman F, Laffel L et al. Care of children and adolescents with type 1 diabetes. Diabetes Care 2005; 28: 186-212.
11. Ludvigsson J, Bolli GB. Intensive insulin treatment in diabetic children. Diabetes Nutr Metab 2001; 14: 292-304.
12. Havelund S, Plum A, Ribel U, Jonassen I, Volund A, Markussen J et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004; 21: 1498-1504.
13. Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614-1620.
14. Jehle PM, Micheler C, Jehle DR, Breitig D, Boehm BO. Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens. Lancet 1999; 354: 1604-1607.
15. De Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7: 73-82.
16. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47: 622-629.
17. Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004; 27: 1081-1087.
18. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004; 26: 724-736.
19. Thalange N, Bereket A, Larsen J, Hiort LC, Peterkova V. Treatment with insulin detemir or NPH insulin in children aged 2-5 years with type 1 diabetes mellitus. Pediatr Diabetes 2011; 12: 632-641.
20. International Conference of Harmonisation (ICH). Topic E6: Harmonised Tripartite Guidelines for Good Clinical Practice, Step 5, Consolidated Guideline 1.5.96. Available at http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf 1996 Last accessed 23 October 2012.
21. World Medical Association (WMA). Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Patients, 52nd WMA General Assembly, Edinburgh, Scotland, October 2000 and last amended with Note of Clarification on Paragraph 29 by the WMA General Assembly 2002, Washington. Available at http://www.fda.gov/ohrms/dockets/dockets/06d0331/06D-0331-EC20-Attach-1.pdf Last accessed 23 October 2012.
22. International Society for Pediatric and Adolescent Diabetes (ISPAD). Guidelines. Available at http://www.diabetesguidelines.com/health/dwk/pro/guidelines/ISPAD/ispad.asp Last accessed 23 October 2012.
23. Clarke W, Jones T, Rewers A, Dunger D, Klingensmith GJ. Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes 2008; 9: 165-174.
24. Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med 1998; 17: 407-429.
25. Tanner JM. Normal growth and techniques of growth assessment. Clin Endocrinol Metab 1986; 15: 411-451.
26. Food and Drug Administration. Code of Federal Regulations, Guidance for Industry, Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. Draft Guidance. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071624.pdf Last accessed 8 December 2010.
27. Ryan C, Gurtunca N, Becker D. Hypoglycemia: a complication of diabetes therapy in children. Pediatr Clin North Am 2005; 52: 1705-1733.
28. Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008; 25: 442-449.
29. Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26: 590-596.
30. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet Med 2007; 24: 27-34.
31. Kilpatrick ES, Rigby AS, Atkin SL. A1c variability and the risk of microvascular complications in type 1 diabetes: data from the DCCT. Diabetes Care 2008; 31: 2198-2202.
32. Barnard K, Thomas S, Royle P, Noyles K, Waugh N. Fear of hypoglycaemia in parents of young children with type 1 diabetes: a systematic review. BMC Pediatr 2010; 10: 50.
33. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.
34. Polonsky WH, Anderson BJ, Lohrer PA, Aponte JE, Jacobson AM, Cole CF. Insulin omission in women with IDDM. Diabetes Care 1994; 17: 1178-1185.
35. Haagen BF. Insulin omission. A troubling trend among adolescent girls. J Psychosoc Nurs Ment Health Serv 2011; 49: 6-7.